Commonwealth Medicine, Clinical Pharmacy Services
Health Services Administration | Health Services Research | Pharmacy and Pharmaceutical Sciences
Pipeline PredictorRx™ evaluates new drugs, expected to have a significant clinical or financial impact when approved by the FDA, and compares them to current therapies.
This UMass Medical School model, entirely independent of drug company interests, goes beyond detailing pharmacy outcomes for pipeline drugs — we also examine the potential for avoiding hospitalization and other medical costs.
Pipeline PredictorRx™, drug evaluation, drug impact, pipeline drugs
Commonwealth Medicine Publications
Cummins T. (2011). Pipeline Predictor Rx. Commonwealth Medicine Publications. Retrieved from https://escholarship.umassmed.edu/commed_pubs/44